Securities code: Jinhe Biotechnology Co.Ltd(002688) securities abbreviation: Jinhe Biotechnology Co.Ltd(002688) Announcement No.: 2022008 Jinhe Biotechnology Co.Ltd(002688)
Announcement on the resolutions of the 17th meeting of the 5th board of supervisors
The company and all members of the board of supervisors guarantee that the contents of the announcement are true, accurate and complete, and are liable for false records, misleading statements or major omissions in the announcement.
Jinhe Biotechnology Co.Ltd(002688) (hereinafter referred to as “the company”) the 17th meeting of the 5th board of supervisors was notified by e-mail on April 8, 2022 and held on site on April 20, 2022. The meeting was presided over by Mr. Zhang qiansui, chairman of the board of supervisors. There were 3 supervisors who should be present and 3 actually present. The number of supervisors attending the meeting of the board of supervisors was in line with laws and regulations, and the meeting was legal and valid. The meeting shall be held in accordance with the company law of the people’s Republic of China and other laws and regulations and the articles of association. The supervisors attending the meeting deliberated and adopted the following proposals by means of on-site voting:
1、 The proposal on the work report of the board of supervisors of the company in 2021 was deliberated and adopted with 3 affirmative votes, 0 negative votes and 0 abstention.
See cninfo.com for details of the work report of the board of supervisors（ http://www.cn.info.com.cn. ）。
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation.
2、 The proposal on the company’s 2021 annual audit report was deliberated and adopted with 3 affirmative votes, 0 negative votes and 0 abstention.
See cninfo.com for details of the audit report（ http://www.cn.info.com.cn. ）。
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation.
3、 The proposal on the company’s 2021 annual financial statement was deliberated and adopted with 3 affirmative votes, 0 negative votes and 0 abstention.
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation.
4、 The proposal on the company’s 2022 financial budget plan was deliberated and adopted with 3 affirmative votes, 0 negative votes and 0 abstention.
See cninfo.com for details of Jinhe Biotechnology Co.Ltd(002688) 2022 annual financial budget plan（ http://www.cn.info.com.cn. ）。
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation.
5、 The proposal on the company’s profit distribution plan for 2021 was deliberated and adopted with 3 affirmative votes, 0 negative votes and 0 abstention.
Audited by ShineWing Certified Public Accountants (special general partnership), the net profit of the company in 2021 was 2374795658 yuan, the statutory surplus reserve was 237479566 yuan, plus the undistributed profit of 36860251301 yuan at the beginning of the year, deducting the profit of 6352896550 yuan of the previous year distributed this year, the profit available for distribution to shareholders in 2021 was 32644670843 yuan.
According to the company’s operation and the need to repay shareholders, the company’s profit distribution plan for 2021 is as follows: no cash dividend, no bonus shares and no conversion of provident fund into share capital in 2021.
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation.
6、 The proposal on the full text and summary of the company’s 2021 annual report was deliberated and adopted with 3 affirmative votes, 0 negative votes and 0 abstention.
After review, the board of supervisors believes that the procedures for the board of directors to prepare and review the Jinhe Biotechnology Co.Ltd(002688) 2021 annual report comply with laws, administrative regulations and the provisions of the CSRC. The contents of the report truly, accurately and completely reflect the actual situation of the listed company, and there are no false records, misleading statements or major omissions.
See cninfo.com for the full text of the 2021 annual report（ http://www.cn.info.com.cn. ）。 See http://www.cninfo.com.cn for details of the summary of 2021 annual report（ http://www.cn.info.com.cn. ）And securities times, Securities Daily, Shanghai Securities News and China Securities News.
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation.
7、 The special report on the use and deposit of the company’s raised funds in 2021 was reviewed and adopted by 3 votes in favor, 0 against and 0 abstention.
The board of supervisors believes that the use and deposit of the company’s raised funds in 2021 comply with the relevant provisions of China Securities Regulatory Commission and Shenzhen Stock Exchange on the use and deposit of raised funds of listed companies, and there is no violation of the use and deposit of raised funds.
See cninfo.com for details of the special report on the deposit and use of the company’s raised funds in 2021（ http://www.cn.info.com.cn. ）。
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation.
8、 The special instructions on the occupation of non operating funds and other related capital transactions of the company in 2021 were reviewed and adopted by 3 votes in favor, 0 against and 0 abstention.
See http://www.cninfo.com.cn for details of the special instructions on the occupation of non operating funds and other related capital transactions in Jinhe Biotechnology Co.Ltd(002688) 2021（ http://www.cn.info.com.cn. ）。
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation.
9、 The proposal on renewing the appointment of ShineWing Certified Public Accountants (special general partnership) as the company’s audit institution in 2022 was deliberated and adopted by 3 votes in favor, 0 against and 0 abstention.
See cninfo.com for details（ http://www.cn.info.com.cn. ）Announcement of Jinhe Biotechnology Co.Ltd(002688) on reappointment of audit institutions in 2021.
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation.
10、 The self-evaluation report on the company’s internal control in 2021 was deliberated and adopted with 3 affirmative votes, 0 negative votes and 0 abstention.
The board of supervisors believes that the self-evaluation report on internal control in 2021 truly and objectively reflects the construction and operation of the company’s internal control system. The board of supervisors has no objection to the self-evaluation report on internal control in 2021.
For details of Jinhe Biotechnology Co.Ltd(002688) 2021 annual internal control self-evaluation report and the opinions of the board of supervisors on 2021 annual internal control self-evaluation report, please refer to cninfo.com（ http://www.cn.info.com.cn. ）。
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation.
11、 The proposal on the estimated related party transactions between the company and Inner Mongolia Jinhe construction and installation Co., Ltd. in 2022 was deliberated and adopted by 3 votes in favor, 0 against and 0 abstention.
See cninfo.com for details（ http://www.cn.info.com.cn. ）Announcement of Jinhe Biotechnology Co.Ltd(002688) on estimated related party transactions with Inner Mongolia Jinhe construction and installation Co., Ltd. in 2022.
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation.
12、 The proposal on the provision of financing guarantee for subsidiaries and secondary subsidiaries expected to be added by the company in 2022 was deliberated and adopted by 3 votes in favor, 0 against and 0 abstention.
See cninfo.com for details of Jinhe Biotechnology Co.Ltd(002688) the announcement on providing financing guarantee for subsidiaries and secondary subsidiaries in 2022（ http://www.cn.info.com.cn. ）。
This proposal shall be submitted to the 2021 annual general meeting of shareholders for deliberation and approval.
13、 The proposal on the provision for asset impairment was reviewed and adopted with 3 in favor, 0 against and 0 abstention.
See cninfo.com for details（ http://www.cn.info.com.cn. ） Jinhe Biotechnology Co.Ltd(002688) announcement on the provision for asset impairment.
14、 Documents for future reference
1. Resolutions of the board of supervisors;
2. Other documents required by Shenzhen Stock Exchange.
It is hereby announced.
Jinhe Biotechnology Co.Ltd(002688) board of supervisors
April 20, 2022
